Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

COMMITMENT

Financiado

Cerrado

Combined Molecular Microscopy for Therapy and Personalized Medication in Rare An...

Combined Molecular Microscopy for Therapy and Personalized Medication in Rare Anaemias Treatments The aim of CoMMiTMenT is the development of combined imaging technologies based on optofluidic microscopy and scanning ion conductance microscopy. An integrated, completely simultaneous device named µCOSMOS will be used as a proof... ver más

30/09/2018

USAAR

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

UNIVERSITAT DES SAARLANDES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-09-30 No tenemos la información de la convocatoria

0% 78% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

USAAR

0.00€ | Lider

ORX

N.D. | Participante

ARIVIS AG

N.D. | Participante

FUNDACIO INSTITUT DE RECERCA...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SEFC Spectrally encoded flow cytometry 164K€ Cerrado

Immuno-OCT In vivo Immunofluorescence-Optical Coherence Tomography 3M€ Cerrado

EQC2021-007527-P PLATAFORMA DE MICROSCOPIA ESPECTRAL, NO-LINEAL Y DE TIEMPO R... 1K€ Cerrado

AXES.Histo Advanced X-ray Energy-sensitive Microscopy for Virtual Hist... 2M€ Cerrado

umCryofix A microfluidic cryofixation method for time resolved correla... 171K€ Cerrado

DR-NANO Depth Resolved Optical Nanoscopy 100K€ Cerrado

Líder del proyecto

UNIVERSITAT DES SAARLANDES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The aim of CoMMiTMenT is the development of combined imaging technologies based on optofluidic microscopy and scanning ion conductance microscopy. An integrated, completely simultaneous device named µCOSMOS will be used as a proof-of-principle for therapeutic interventions in rare anaemias. Both techniques rely on molecular detection: optofluidic microscopy relies on molecular biomarkers, and scanning ion conductance microscopy on functional imaging of molecular structures. µCOSMOS allows for the exploration, diagnosis and development of therapeutic interventions for several rare anaemias, including hereditary xerocytosis, overhydrated hereditary stomatocytosis, familial pseudohyperkaliemia, cryohydrocytosis, certain types of spherocytosis, hereditary spherocytosis, sickle cell anaemia, thalassemia and phosphofructokinase deficiency. The non-invasive nature of the combined imaging technologies, which probe the function of molecular effectors, facilitates the testing of medications and their dosage in a personalised manner. For some of the rare anaemias, CoMMiTMenT will provide an initial proof-of-principle, whereas for others, such as sickle cell anaemia, personalised medical interventions should become available and will be tested in clinical practice within the project. CoMMiTMent will ensure an effective therapy with diminished undesirable adverse effects, largely replacing splenectomy. CoMMiTMenT includes clinical partners and builds a strong relationship with the European Network for Rare and Congenital Anaemias (ENERCA). Furthermore, CoMMiTMenT acts as a bridge between the technology-driven SMEs and ENERCA and, as such, supports the competitiveness of Europe in this area. The applications will advance (personalised) treatment of rare anaemias and, therefore, contribute to the goal of the International Rare Diseases Research Consortium (IRDiRC) to deliver novel diagnostic modalities and 200 new therapies for rare diseases by 2020.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores